March 28, 2022 6:10pm

The Biostage Chronicles: closed up +$0.25 with 13,012 shares traded after Friday’s+$0.44 with 1,978 shares traded after being FLAT most of week) who is buying - non-U.S. Chinese nationals to “PROP-UP” past over-priced PPMs (private placements) to reverse shares to public holdings to facilitate some sort of financial offering

Pre-open indications: 4 Hits, 2 MISS and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The metrics say it all … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

 


If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +94.65 points (+0.27%); the S&P closed UP +32.46 points +0.71(%) while the Nasdaq closed UP +185.60 points (+1.31%)

 

Henry’omics:

Indexes rose on Monday, extending some weeks of gain, as investors shook off recession concerns and bid cell and gene therapy sector shares lower.

The Dow closed slightly higher on Monday, after erasing earlier losses. The major indexes all rallied into the close while the Nasdaq led. The bullish late-day move on Monday came after all three benchmark indexes closed higher for their second-straight week on Friday. <IBD>

Also boosting sentiment, the Cboe volatility index, known as the fear gauge, closed below 20 for the first time since Jan. 14.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday opened negative at 28 up/5 downs, 2 flats, stayed negative at the mid-day at 6/29 and 0 flat, ending with a negative close of 13/20 and 2 flats;

 

Pre-open Indications: 4 Hits <BUY: AxoGen (AXGN +$0.08), Ionis Pharmaceuticals (IONS-$0.79), Mesoblast (MESO -$0.10), uniQure NV (QURE -$0.34)> 2 Miss < Intellia Therapeutics (NTLA +$2.43), BioLife Solutions (BLFS +$0.30)> 1 pimp/pump/promote < Biostage (BSTG +$0.26)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (VSTM, BCLI) added with 31 to date

 

Key Metrics:

Monday - Sector volume was LOW with 2 of the 13-upside having higher than the 3-month average volume with LOW volume of 4 of 20-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +0.71% and the XBI was up +0.10%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -1.18 points or -5.67% at 19.63

 

Jumping with share pricing momentum (10 of 13):

  • Intellia Therapeutics (NTLA +$2.43 after Friday’s -$1.36),
  •  Vericel (VCEL +$1.52 after Friday’s -$0.33),
  • Sage Therapeutics (SAGE +$1.29 after Friday’s -$1.22),
  • Beam Therapeutics (BEAM +$1.03 after Friday’s -$0.65),
  • Global Blood Therapeutics (GBT +$0.84 after Friday’s -$0.41),
  • CRISPR Therapeutics (CRSP -+$0.69 after Friday’s -$2.26),
  • BioLife Solutions (BLFS -+$0.30 after Friday’s -$1.16),
  • Biostage (BSTG +$0.25 with 13,012 shares traded after Friday’s+$0.44 with 1,978 shares traded after being FLAT most of week),
  • Verastem Oncology (VSTM +$0.12),
  • Caribou Biosciences (CRBU +$0.12 after Friday’s -$0.29),

Hammered in today’s market (10 of 20):

  • Alnylam Pharmaceuticals (ALNY -$2,16 after Friday’s +$0.11),
  • Voyager Therapeutics (VYGR -$0.97),
  • Ultragenyx (RARE -$0.90),
  • Ions Pharmaceuticals (IONS -$0.79),
  • Chinook Therapeutics (KDNY -$0.46 after Friday’s +$0.06),
  • uniQure NV (QURE -$0.34 after Friday’s -$0.59),
  • Bellicum Pharmaceuticals (BLCM -$0.19 after Friday’s +$0.05,
  • Brainstorm Cell Therapeutics (BCLI -$0.15),
  • Cellectis SA (CLLS -$0.12),
  • Mesoblast (MESO -$0.10),

 

March, Q1/2022:

  • Monday closed negative with 13 incliners, 20 decliners and 2 flats
  • Friday closed negative with 7 incliners and 28 decliners

 

The BOTTOM LINE: What and which slipped down; it’s sector physiology as risk and volatility goes both ways.

As I stated this a.m., “A list that keeps growing: Resistance mired by sentiment, focus, earnings and low volume volatility, geopolitics, accentuated by quarterly option expirations on Friday and potentially subverted by the March jobs and economic reporting

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought – two (2) this week: FIXX and CRBU.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.